Effect of GenF20 Plus on serum IG F-1 levels in healthy adults: a randomized controlled study

This article is about the randomized, double-blind, placebo-controlled 12-week trial enrolled 70 healthy adults (35 per group; 61 completed per-protocol) to test whether GenF20 Plus raises fasting serum IGF-1. In the primary analysis IGF-1 increased in both groups but the between-group difference was not statistically significant (GenF20 +13.46 ± 36.12 ng/mL vs placebo +6.35 ± 36.56 ng/mL).

A post-hoc subgroup analysis in participants aged ≥40 years—using ANCOVA to adjust for baseline differences—reported a statistically significant adjusted increase in IGF-1 with GenF20 (adjusted change GenF20 +22.69 ± 40.62 ng/mL vs placebo −4.31 ± 16.79 ng/mL). There were no significant between-group differences for anthropometry, body composition, or subjective measures (memory, libido, energy, sleep), with improvements in some subjective outcomes seen in both groups.

Adverse events were mostly mild and there were no serious events; labs and vitals showed no clinically important changes. The authors conclude that while there is a signal for increased IGF-1 in older participants, the finding arose from a post-hoc subgroup and a per-protocol analysis in a small, short trial, limiting confidence—larger, longer, pre-specified trials are needed to confirm efficacy and safety. 

Click Here To View The Full Article